Effect of specific immunotherapy versus loratadine on serum adhesion molecules.

Allerg Immunol (Paris)

Faculty of Medicine, CHIUL, Immunoallergology Unit, Hospital Santa Maria, Lisbon, Portugal.

Published: October 2001

Objective: To evaluate comparatively the effect on serum ICAM-1 and VCAM-1 values of specific immunotherapy versus loratadine in the treatment of allergic rhinitis.

Population: 65 patients with mild to moderate House Dust Mite allergic rhinitis.

Methods: Patients were divided into three groups, according to patients' preference: a control group with patients receiving only rescue therapy (antihistamines and/or nasal cromoglycate when needed); an antihistamine group with patients receiving daily loratadine 10 mg (and nasal cromoglycate as rescue therapy); an immunotherapy group with patients receiving subcutaneous house dust mite specific immunotherapy (and antihistamines or nasal cromoglycate when needed). In all groups we measured soluble ICAM-1 and VCAM-1 serum levels before the start of the study period and at the end of the study period. The duration of the study was one year for the control group and for the immunotherapy group. In patients taking daily antihistamines we measured serum adhesion molecules one month after the beginning of the therapy. We used Student's T test for statistical analysis.

Results: Patients in the control group didn't have significant variations in serum ICAM-1 (p = 0.239) or VCAM-1 (p = 0.38) levels. Patients receiving loratadine showed significant decreases in serum VCAM-1 levels (p = 0.0012) but not in serum ICAM-1 levels (p = 0.224). Patients receiving immunotherapy also showed a similar pattern, with significant decreases in serum VCAM-1 levels (p = 0.012) but not in serum ICAM-1 levels (p = 0.254).

Conclusions: Specific house dust mite immunotherapy and regular daily loratadine therapy are able to lower significantly serum levels of soluble VCAM-1. However, this effect, which can be interpreted as an anti-inflammatory action, is not applied to soluble ICAM-1 levels, which raises the possibility of a differential action of these therapies on the mechanisms of allergic inflammation. Patients on rescue medication alone did not show any significant differences in these parameters.

Download full-text PDF

Source

Publication Analysis

Top Keywords

patients receiving
20
serum icam-1
16
group patients
16
specific immunotherapy
12
house dust
12
dust mite
12
control group
12
nasal cromoglycate
12
icam-1 levels
12
serum
10

Similar Publications

Effect of Capromorelin on Appetite and Weight Gain of Domestic Pigeons ().

J Avian Med Surg

January 2025

Department of Small Animal Medicine and Surgery (Zoological Medicine), University of Georgia College of Veterinary Medicine, Athens, GA 30602, USA,

Weight loss and decreased appetite are commonly encountered sequela of disease and stress in avian patients. However, there is currently minimal information in the veterinary literature regarding appetite stimulation in birds. Capromorelin is a potent agonist of the growth hormone secretagogue receptor and increases food consumption via direct stimulation of the hunger centers of the hypothalamus.

View Article and Find Full Text PDF

Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab (Ophthalmol Retina. 2024;8:733-743).

Ophthalmol Retina

January 2025

Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Population Health Data Center, National Cheng Kung University, Tainan, Taiwan. Electronic address:

View Article and Find Full Text PDF

Intelligent Analgesia Management System in Postoperative Pain Management: A Retrospective Analysis.

J Perianesth Nurs

January 2025

Department of Nursing, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.

Purpose: This study aimed to explore the effect of an intelligent analgesia management system on postoperative pain management and the working mode of acute pain service.

Design: This is a retrospective cohort study.

Methods: A total of 584 patients who underwent laparoscopic abdominal surgery under general anesthesia and voluntarily received intravenous patient-controlled analgesia (PCA) between January 2018 and April 2020 at our hospital were selected.

View Article and Find Full Text PDF

Outcomes for Children With Congenital Heart Disease Undergoing Ventricular Assist Device Implantation: An ACTION Registry Analysis.

J Am Coll Cardiol

December 2024

Division of Cardiology, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Background: There are no contemporary reports that highlight the national outcomes for children with congenital heart disease (CHD) undergoing ventricular assist device (VAD) implantation.

Objectives: This study sought to evaluate differences in VAD outcomes for children with CHD to those with non-CHD as well as those with univentricular CHD to those with biventricular CHD.

Methods: Data for CHD and non-CHD patients from the multicenter ACTION (Advanced Cardiac Therapies Improving Outcomes Network) undergoing VAD implantation from April 2018 to February 2023 were included.

View Article and Find Full Text PDF

Background: Myocardial fibrosis is a key healing response after myocardial infarction driven by activated fibroblasts. Gallium-68-labeled fibroblast activation protein inhibitor ([Ga]-FAPI) is a novel positron-emitting radiotracer that binds activated fibroblasts.

Objectives: The aim of this study was to investigate the intensity, distribution, and time-course of fibroblast activation after acute myocardial infarction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!